Search
# Popular search #
中文站
# Popular search #
From June 5 to 8, 2026, the American Diabetes Association's 86th Scientific Sessions will be held at the Ernest N. Morial Convention Center in New Orleans, USA. As a leading biopharmaceutical company in China, Gan & Lee Pharmaceuticals. (hereinafter referred to as "Gan & Lee", stock code: 603087.SH) will showcase four of its latest clinical research findings at this year's annual meeting.
The American Diabetes Association's Scientific Sessions is one of the world's largest and most influential academic conferences in the field of diabetes. This event is expected to attract over 12,000 clinical experts, researchers, healthcare practitioners, and industry representatives from across the globe. It serves as a premier platform for discussing cutting-edge breakthroughs in diabetes prevention and management, and for presenting the latest progress in research and drug development.
At this conference, four abstracts from Gan & Lee have been officially selected for presentation. These include the company's self-developed Class 1 innovative drugs: the bi-weekly GLP-1 receptor agonist Bofanglutide (GZR18) injection, the once-weekly basal insulin GZR4 injection, and the once-weekly fixed-ratio combination (FRC) of basal insulin/GLP-1RA, GZR102 injection. The latest clinical data for these products will be publicly disclosed for the first time via e-poster presentations.
The accepted abstracts have been authorized for publication in Diabetes®, the official journal of the American Diabetes Association's 86th Scientific Sessions. The on-site presentation session is scheduled for June 7, from 12:30 PM to 1:30 PM (CDT) in the Poster Hall (Halls D-E) of the Ernest N. Morial Convention Center.
Bi-weekly GLP-1RA: Bofanglutide (GZR18) Injection
Title: Effect of Bofanglutide on the Pharmacokinetics of Metformin in Healthy Participants
Category: 12-D Clinical Therapeutics - Other Therapeutic Agents
Abstract No.: 1699-P
Presentation Time: June 7, 2026, 12:30–1:30 PM (CDT)
Title: Effect of Renal Impairment on the Pharmacokinetics and Safety of Bofanglutide
Category: 12-D Clinical Therapeutics - Other Therapeutic Agents
Abstract No.: 1720-P
Presentation Time: June 7, 2026, 12:30–1:30 PM (CDT)
Once-weekly Insulin: GZR4 Injection
Title: Effects of Moderate Renal Impairment on Pharmacokinetics and Safety of Once-weekly Insulin GZR4
Category: 12-C Clinical Therapeutics - Insulins
Abstract No.: 1745-P
Presentation Time: June 7, 2026, 12:30–1:30 PM (CDT)
Once-weekly Basal Insulin/GLP-1RA Fixed-Ratio Combination: GZR102 Injection
Title: Pharmacokinetic and Pharmacodynamic Profiles of GZR102 Injection, a Novel Once-Weekly Fixed-Ratio Combination of Insulin GZR4 and GLP-1 Analog Bofanglutide
Category: 12-D Clinical Therapeutics - Other Therapeutic Agents
Abstract No.: 1822-P
Presentation Time: June 7, 2026, 12:30–1:30 PM (CDT)
Exhibition Hours: June 6–8, 10:00 AM – 4:00 PM (CDT)
Venue: Ernest N. Morial Convention Center – New Orleans, LA
Booth Number: #1001
Gan & Lee remains committed to its core corporate philosophy of "Science & Excellence," focusing on in-depth R&D and continuous innovation with a global vision. As a leader in Chinese biopharmaceuticals, we aim to drive breakthroughs in the diagnosis and treatment of metabolic diseases through active participation in international academic exchanges. We are dedicated to providing safer and more effective treatment solutions for patients worldwide. We sincerely invite colleagues from all sectors to join us in exploring the academic frontiers at this year's American Diabetes Association's 86th Scientific Sessions and to work together in elevating the treatment of metabolic diseases to new heights.
About Gan & Lee
Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company and the first in China to master industrial-scale manufacturing technologies for recombinant insulin analogs. The Company has established a comprehensive insulin research and development pipeline.
Currently, Gan & Lee offers six core insulin products, including five insulin analogs: insulin glargine injection (Basalin®; EU brand name Ondibta®), insulin lispro injection (Prandilin®; EU brand name: Bysumlog®), insulin aspart injection (Rapilin®; EU brand name: Dazparda®), premixed insulin lispro protamine suspension injection (25R) (Prandilin®25), and insulin aspart 30 injection (Rapilin®30); as well as one human insulin product, premixed human insulin protamine suspension injection (30R) (Similin®30), together with related delivery devices. These products cover the long-acting, rapid-acting, and premixed insulins.
In China's second round of national volume-based procurement for insulin, Gan & Lee ranked first among selected companies by contracted volume for insulin analogs, further strengthening its domestic market position. In parallel, the Company continues to advance its international expansion. Insulin glargine injection has received marketing authorization from the European Commission (EC), while for insulin lispro injection and insulin aspart injection, it has received the positive opinion from CHMP of EMA. Gan & Lee is steadily progressing toward its goal of becoming a key global participant in the field of metabolic diseases.
Looking forward, Gan & Lee is committed to achieving comprehensive coverage across the diabetes treatment landscape and further enhancing its competitive position in this therapeutic area. The Company will also actively pursue the development of innovative chemical drugs and biologics, with a strategic focus on metabolic diseases, cardiovascular diseases, and other therapeutic areas.
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.